LYNPARZA (OLAPARIB): LATEST DATA SUGGEST POTENTIAL OVERALL SURVIVAL ADVANTAGE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
AstraZeneca presented (at ASCO in the evening of June 5) results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial.